William Blair Issues Negative Forecast for Zoetis Earnings

Zoetis Inc. (NYSE:ZTS) – Research analysts at William Blair lowered their Q1 2025 earnings estimates for shares of Zoetis in a research report issued to clients and investors on Thursday, February 13th. William Blair analyst B. Vazquez now expects that the company will earn $1.37 per share for the quarter, down from their previous forecast of $1.38. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. William Blair also issued estimates for Zoetis’ Q1 2025 earnings at $1.37 EPS, Q2 2025 earnings at $1.59 EPS, Q2 2025 earnings at $1.59 EPS, Q3 2025 earnings at $1.62 EPS, Q3 2025 earnings at $1.62 EPS, Q4 2025 earnings at $1.47 EPS, Q4 2025 earnings at $1.47 EPS, FY2025 earnings at $6.05 EPS, Q1 2026 earnings at $1.52 EPS, Q1 2026 earnings at $1.52 EPS, Q2 2026 earnings at $1.74 EPS, Q2 2026 earnings at $1.74 EPS, Q3 2026 earnings at $1.76 EPS, Q3 2026 earnings at $1.76 EPS, Q4 2026 earnings at $1.62 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $6.64 EPS and FY2026 earnings at $6.64 EPS.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion.

Several other brokerages have also commented on ZTS. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, Piper Sandler decreased their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus target price of $214.90.

Zoetis Stock Performance

Shares of ZTS opened at $156.43 on Monday. The company’s fifty day moving average is $168.10 and its 200-day moving average is $178.61. Zoetis has a 12 month low of $144.80 and a 12 month high of $200.53. The firm has a market cap of $70.58 billion, a price-to-earnings ratio of 29.40, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new position in Zoetis during the third quarter valued at approximately $31,000. First Personal Financial Services acquired a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Dunhill Financial LLC boosted its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC boosted its holdings in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.